On this episode of “5 Award Profitable Minutes With,” our host, Stephen Seidel of The Seidel Company, takes the time to talk with an inspiring entrepreneur doing nice work in our group. On this phase, Stephen speaks with Ayla Annac of InvivoSciences, Inc.
InvivoSciences, Inc. (IVS) is a pre-clinical-stage biotech firm creating therapies for cardiovascular and cardiometabolic ailments. Our innovation makes use of its predictive precision drugs improvement expertise platform, Kokordia
, combining patient-derived micro coronary heart on a chip, NuHeart, AI-assisted patient-stratification diagnostic expertise, and automatic instrumentation for precision drugs improvement. IVS201 is our lead drug improvement program focusing on coronary heart failure with preserved ejection fraction (HFpEF).
Coronary heart failure (HF), corresponding to HFpEF, is a fancy illness with totally different subgroups, the place affected person stratification is the important thing to advancing a focused remedy in ever-challenging HF drug improvement. Our first pipeline, IVS201, is a repurposed drug candidate for treating a uncommon HFpEF, outlined by our AI-assisted affected person stratification expertise.
View unique put up: 5 Award Profitable Minutes With Ayla Annac of InvivoSciences, Inc. on Every day Information Community.
This put up was initially revealed on Every day Information Community.